About Us
We are a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need.
We are committed to pursuing severe rare diseases with well-defined biology that can be targeted with therapies tailored to patients’ needs.
We are headquartered in Basel, Switzerland, with business operations in the New York area.

Our Mission
We are on a mission to build a leading, fully integrated global severe rare disease company using our patient-centric approach to identify and develop transformative medicines for the treatment of severe rare diseases.
Meet Our Team
We have a world-class team with deep expertise in severe rare diseases and a track record of success in research and development, commercialization and business development for innovative products targeting orphan conditions with high unmet medical needs.
We value and model the passion, energy and entrepreneurial mindset necessary to develop life-changing therapeutics.
Management Team

Luca Santarelli, M.D.
Founder and Chief Executive Officer and Board Member

Claudia D’Augusta, Ph.D.
Chief Financial Officer

Christian Meyer, M.D., Ph.D.
Chief Operating Officer

Omar Khwaja, M.D., Ph.D.
Chief Medical Officer

Kevin Harris, MBA
Chief Commercial Officer

Scott Applebaum
Chief Legal Officer and Corporate Secretary

Alain Bernard, Ph.D.
Chief Technology Officer

Martine Mazzetti, MsPharm
Chief of Staff

Nader N. Youssef M.D., MBA, FACG
Senior Vice President, Global Medical Affairs and Patient Partnership

Michael Steininger
Senior Vice President, Head of Human Resources
Board of Directors

Thomas F. Woiwode, Ph.D.
Board Member and Chair

Paul R. Carter
Board Member

Wouter Joustra
Board Member

Sandip Kapadia, MBA, CPA
Board Member

Luca Santarelli, M.D.
Founder and Chief Executive Officer and Board Member

Hans Schikan
Board Member

Murray Stewart, DM, FRCP
Board Member